does retatrutide Is Weight Loss the Future of Peptide Weight Loss Therapy? Retatrutide: Fat Loss, Liver Health
Description
In the ACHIEVE-3 Phase 3 trial, orforglipron was superior to oral semaglutide on both HbA1c reduction (approximately 2.2 vs 1.4 percentage points) and weight loss
As the first glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, tirzepatide offers distinct pharmacological advantages over existing incretin-based therapies
[DOI] [PubMed] [Google Scholar] 229.Yun S.P., Kam T.I., Panicker N., Kim S., Oh Y., Park J.S
Ozempic (semaglutide) has dominated the GLP-1 market due to its early approval, strong efficacy in glycemic control, and weekly administration convenience
